JACQUI Trademark

Trademark Overview


On Wednesday, January 27, 2021, a trademark application was filed for JACQUI with the United States Patent and Trademark Office. The USPTO has given the JACQUI trademark a serial number of 90492327. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, October 28, 2024. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The JACQUI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
jacqui

General Information


Serial Number90492327
Word MarkJACQUI
Filing DateWednesday, January 27, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, October 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 21, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 29, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Saturday, January 30, 2021NEW APPLICATION ENTERED
Thursday, April 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 13, 2021ASSIGNED TO EXAMINER
Tuesday, August 17, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 1, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 21, 2021PUBLISHED FOR OPPOSITION
Tuesday, September 21, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 10, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 10, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 10, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, November 10, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 16, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 16, 2022NOTICE OF ALLOWANCE CANCELLED
Monday, June 20, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, June 21, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Thursday, June 23, 2022TEAS PETITION TO REVIVE RECEIVED
Thursday, June 23, 2022PETITION TO REVIVE-GRANTED
Thursday, June 23, 2022NOTICE OF REVIVAL - E-MAILED
Friday, July 29, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 29, 2022NEW NOA TO ISSUE
Tuesday, September 6, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 22, 2023SOU EXTENSION 1 FILED
Wednesday, February 22, 2023SOU EXTENSION 1 GRANTED
Friday, February 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 1, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 1, 2023SOU EXTENSION 2 FILED
Friday, September 1, 2023SOU EXTENSION 2 GRANTED
Tuesday, September 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 1, 2024SOU TEAS EXTENSION RECEIVED
Friday, March 1, 2024SOU EXTENSION 3 FILED
Friday, March 1, 2024SOU EXTENSION 3 GRANTED
Saturday, March 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 6, 2024SOU EXTENSION 4 FILED
Monday, October 7, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, October 7, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, October 15, 2024NOTICE OF REVIVAL - E-MAILED
Tuesday, October 15, 2024TEAS PETITION TO REVIVE RECEIVED
Tuesday, October 15, 2024PETITION TO REVIVE-GRANTED
Monday, October 28, 2024SOU EXTENSION 4 GRANTED
Monday, October 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED